New Treatments & Clinical Trials for Esophageal Cancer

Esophageal cancer is diagnosed in about 21,000 Americans each year, often at advanced stages because early symptoms are subtle. Treatment typically combines chemotherapy, radiation, and surgery, but outcomes remain challenging. Research is now focused on targeted drugs, immunotherapy, and less invasive surgical approaches.

What's actually going on in research

Trials are testing checkpoint inhibitors like pembrolizumab and nivolumab earlier in treatment, targeted drugs against HER2 and FGFR2, and combinations that may shrink tumors before surgery. Researchers are studying ways to identify who responds to immunotherapy, testing minimally invasive surgery techniques, and exploring ablation methods for early-stage disease.

What to know before you search

Eligibility typically depends on cancer stage, location in the esophagus, cell type (adenocarcinoma or squamous), prior treatments, and specific biomarkers like HER2 or PD-L1 status.

What types of trials are currently open

• Neoadjuvant trials — Testing treatments given before surgery to shrink tumors, often combining chemotherapy, radiation, and immunotherapy.
• Targeted therapy trials — Testing drugs aimed at specific mutations like HER2 or FGFR2, usually for advanced disease.
• Immunotherapy trials — Testing checkpoint inhibitors alone or combined with chemotherapy, at various stages of disease.
• Surgical technique trials — Comparing minimally invasive surgery to traditional approaches, or testing ways to preserve the esophagus in early cancer.
• Biomarker studies — Collecting tissue and blood samples to identify who responds to treatment and why, looking at factors like PD-L1 levels and tumor mutation burden.